New U.S. Government Policy for Stopping High-Risk Life Sciences Research
About BSAA Brown Bag Sessions
BSAA Brown Bag Discussions are designed to be interactive, practical, and community driven. These sessions are not traditional webinars. They are facilitated conversations where participants engage directly with peers to explore complex, real-world biosafety challenges.
Program Overview
BSAA Members’ Brainstorming session to discuss the New U.S. Government Policy. During this Brown Bag Session, we will be providing an overview of the new policy provided below. In addition, we will gather members’ questions as we prepare for a webinar that BSAA plans to hold on Wednesday, August 26, 2026.
White House Releases New U.S. Government Policy for Stopping High-Risk Life Sciences Research
Today, the Administration released the U.S. Government Policy for Stopping High-Risk Life Sciences Research, pursuant to Executive Order (EO) 14292 on "Improving the Safety and Security of Biological Research."
This new government-wide policy defines areas of life sciences research that pose the greatest risk to our nation's security, implements federal funding prohibitions, and establishes a framework for addressing risk and ensuring compliance. In addition to banning federal support for dangerous gain-of-function research, the policy introduces enhanced review and reporting requirements for all life sciences research, including independent, top-down assessments for projects that may increase the harmful consequences of biological agents, and introduces new restrictions for research conducted outside of the United States.
As NIH implements this policy for the science it supports, we will work closely with the research community to reinforce the shared responsibility of every scientist to thoughtfully evaluate the potential benefits and risks of every experiment and ensure that biomedical research advances safely, responsibly, and in service of the American people.
For more information on NIH’s implementation of the Policy, please see a statement issued today by NIH Director, Dr. Jay Bhattacharya, as well as a notice NIH has published in its Guide to Grants and Contracts.
Interactive Discussion Format
✔ Brief framing overview to set context
✔ Facilitated discussion using the dGOF Review Rubric
✔ Real-time Q&A and peer exchange
✔ Opportunity to compare institutional approaches
✔ Open dialogue on challenges, gray areas, and best practices
Who Should Attend
- Biosafety Officers and Biosafety Professionals
- IBC Administrators and Members
- Research Compliance Professionals
- Anyone responsible for reviewing or reporting unanticipated research outcomes
Why Attend
✔ Gain practical insight into identifying potential dGOF events
✔ Strengthen your confidence in making reporting decisions
✔ Learn how others are approaching these challenges
✔ Engage in open, candid discussion in a peer-based environment
✔ Take advantage of exclusive BSAA member programming
Key Takeaway
If an unanticipated outcome occurred in your program today—would you recognize it, and would you know what to do next?
Guest Speaker
Michael Betteken, PhD, CPBCA, Compliance Manager, IBC, ESCRO, DURC, Office of Research Integrity and Assurance, Cornell University
Standing BSAA Faculty
Bill Greer
Assistant Vice President for Research, University of Michigan
Bill Greer is a nationally recognized leader in research compliance with more than 35 years of experience spanning academia, industry, and nonprofit professional organizations. At the University of Michigan, he oversees institutional programs for animal care and use, biosafety, laboratory safety, controlled substances, and emerging autonomous systems.
Bill began his career in industry as a production manager and safety director at Intervet (formerly Tri Bio Laboratories) before transitioning to higher education, where he has held senior roles including Associate Director for Research Compliance, IACUC Vice-Chair, and Biosafety Committee Chair at The Pennsylvania State University. He earned his degree in Microbiology from The Pennsylvania State University.
In 2005, Bill founded the Research Administrators’ Best Practice Meetings, creating a nationally respected forum for research oversight professionals to address real-world programmatic challenges. He continues to facilitate multiple Best Practice Meetings annually focused on biosafety and animal care and use programs.
Bill also chaired the founding committee of the IACUC Administrators Association (IAA) in 2010 and continues to serve as its president and board chair. Since 2007, he has served as an ad hoc consultant to AAALAC International, conducting institutional program reviews and assessments. A frequent speaker and educator, Bill regularly presents at PRIM&R, AALAS, BTAA, C3, and BSAA-sponsored programs, supporting both IBC and IACUC administrative communities nationwide.
Jonah Lee, PhD
Senior Associate Director, University of Michigan
Dr. Jonah Lee brings deep scientific expertise and administrative leadership to biosafety and animal research oversight, with a strong focus on enhancing researcher experience while maintaining regulatory rigor. In his role at the University of Michigan, he provides thought leadership, program oversight, and process optimization across the Animal Care & Use Program.
Working closely with research administration and academic leadership, Dr. Lee leads the strategic development of research engagement infrastructure and institutional support resources. His background in biomedical sciences includes extensive research in stem cell biology and regenerative medicine, with a focus on aging skeletal muscles.
Dr. Lee completed postdoctoral training at the Center for Muscle Biology at the University of Kentucky and has led federally funded research involving both small and large animal models across multiple departments. His combined experience as a scientist and administrator brings a practical, researcher-informed perspective to biosafety and compliance discussions.
Andrew Maksymowych, PhD
Associate Director, Biosafety Programs, University of Pennsylvania
Andrew Maksymowych has more than three decades of experience in research, teaching, and biosafety oversight. Since 2006, he has served at the University of Pennsylvania as Associate Director for Biological Safety Programs, Institutional Biosafety Officer, IBC Administrator, and Institutional Contact for Dual Use Research.
Andrew serves on multiple institutional advisory committees, including the Vice Provost for Research Human Research Advisory Committee, the Human Stem Cell Research Advisory Committee, and the Cadaver and Body Parts Oversight Committee. He holds a B.S. and M.S. from Villanova University and a PhD in Biochemistry from Bryn Mawr College.
Prior to Penn, Andrew held a faculty appointment at Thomas Jefferson University, where his research focused on protein structure-function relationships, including neurotoxins affecting the human nervous system - most notably botulinum neurotoxins. An active BSAA contributor since attending his first Best Practice Meeting in 2015, Andrew remains deeply engaged in advancing biosafety education and professional collaboration.
Raymond F. Scheetz, MS, RBP
Institutional Biosafety Officer & Compliance Manager, Penn State College of Medicine
Ray Scheetz serves as Institutional Biosafety Officer and Compliance Manager at the Penn State College of Medicine within the Research Quality Assurance Office. He oversees all aspects of biosafety compliance, including protocol reviews, biosafety training, annual laboratory surveys, emergency response coordination, and equipment and asset management.
Ray is an active member of the Institutional Biosafety Committee, Research Mission Team, and institutional research emergency task forces. In addition to his institutional role, he serves as a biosafety consultant for Clinical Biosafety Services (CBS) / Shield Consulting.
Previously, Ray spent 25 years as a Laboratory Manager in the Department of Microbiology and Immunology at Penn State College of Medicine, where he managed a BSL-3 facility and supported complex infectious disease research programs. His extensive operational experience provides a grounded, practical perspective on biosafety program implementation.